No standard treatments for the sometimes deadly disorder have been developed, but that may change due to the newly published ...

Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

Three distinct snapshots obtained with cryo-electron microscopy illustrate the arrangement of two of the four symmetrical subunits that make a functional NMDA receptor. During activation, as the ...

GRIN Therapeutics begins patient dosing in global phase 3 Beeline trial of investigational radiprodil for GRINRelated neurodevelopmental disorder: New York Monday, January 12, 202 ...

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).